Below are the financial statements of Ascendis Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 | 2023 |
|---|---|---|
| Revenue | 363.64a | 266.72a |
| Cost of sales | -44.26a | -44.4a |
| Gross profit | 319.38a | 222.32a |
| Research and development costs | -307a | -413.45a |
| Selling, general and administrative expenses | -291.14a | -264.41a |
| Operating profit/(loss) | -278.76a | -455.54a |
| Share of profit/(loss) of associates | -20.06a | -18.4a |
| Finance income | 25.61a | 43.86a |
| Finance expenses | -100.03a | -44.07a |
| Profit/(loss) before tax | -373.24a | -474.14a |
| Income taxes (expenses) | -4.84a | -7.3a |
| Net profit/(loss) for the year | -378.08a | -481.45a |
| Attributable to owners of the company | -378.08a | -481.45a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.